|

TGFBR2 KO CAR27/IL-15 NK cells Clinical Trials

2 actively recruiting trials across 1 location

▼ -1 trial since July 2026

Pipeline

Phase 1: 1Phase 1/2: 1

Top Sponsors

  • M.D. Anderson Cancer Center2

Indications

  • Cancer2
  • Lymphoid1
  • Myeloid Malignancies1
  • Hodgkin Lymphoma1

Houston, Texas2 trials

A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies

The University of Texas M. D. Anderson Cancer Center

Phase 1/2
Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies

The University of Texas M. D. Anderson Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.